Al­to touts new PhI­Ia de­pres­sion da­ta with plans to keep charg­ing for­ward

SAN FRAN­CIS­CO — Pri­vate biotech Al­to Neu­ro­science re­vealed new da­ta Tues­day morn­ing for a psy­chi­atric drug it’s so ex­cit­ed about that a fol­low-up study is al­ready en­rolling.

Al­to tout­ed open-la­bel Phase IIa re­sults for lead pro­gram AL­TO-100, in which the biotech ex­am­ined im­prove­ments in a de­pres­sion symp­tom rat­ing scale known as MADRS. Re­searchers com­pared the change in MADRS scores for pa­tients with and with­out pre-de­fined bio­mark­ers, and the dif­fer­ence proved sta­tis­ti­cal­ly sig­nif­i­cant in both monother­a­py and ad­junc­tive co­horts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER